Basharat Ali | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Basharat Ali | Drug Discovery and Development | Pakistan

University of Baltistan | Pakistan

Assist. Prof. Dr. Basharat Ali is a distinguished researcher and academician specializing in medicinal chemistry, heterocyclic synthesis, and polymer science with extensive expertise in designing and synthesizing biologically active compounds. Currently serving as an Assistant Professor in the Department of Chemistry at the University of Baltistan, Skardu, Pakistan, he has a diverse academic and research background, including postdoctoral research at the College of Pharmaceutical Science, Soochow University, China, where he contributed to the development of chemiluminescent dioxetane probes for disease diagnosis, fluorescent probes for hydrogen sulfide detection, and anthraquinone derivatives as anti-infective agents. He has also worked as a research assistant at Zhejiang University, China, focusing on mechanistic studies of olefin polymerization using α-Diimine nickel(II) catalysts, and at the HEJ Research Institute of Chemistry, University of Karachi, where he specialized in synthetic organic chemistry and bioactive heterocycles.Dr. Basharat Ali’s research interests include the synthesis, structural modification, and biological evaluation of medicinally important synthetic derivatives, probe design for environmental and biomedical applications, multicomponent reactions, polymer synthesis, and catalytic system development. He has supervised numerous postgraduate students and contributed extensively to the field with multiple high-impact publications in reputable international journals. Some of his significant research publications include Synthesis and biological evaluations of 1,3,4-thiadiazole derivatives as dual acting enzyme inhibitors to target inflammation and diabetes, Carbothioamides as anticancer agents: synthesis, in-vitro activity, structure-activity relationship evaluations and molecular docking, Synthesis of (E)-3-(aryl)-1-phenylprop-2-en-1-one Chalcone Derivatives for Hyperglycemic Effect in Diabetes.

Profile: Google Scholar

Featured Publications

Li, S., Zhan, L., Zhao, W., Zhang, S., Ali, B., Fu, Z., Lau, T. K., Lu, X., Shi, M., Li, C. Z., … (2018). Revealing the effects of molecular packing on the performances of polymer solar cells based on A–D–C–D–A type non-fullerene acceptors. Journal of Materials Chemistry A, 6(25), 12132–12141.

Ali, F., Khan, K. M., Salar, U., Iqbal, S., Taha, M., Ismail, N. H., Perveen, S., … (2016). Dihydropyrimidones: As novel class of β-glucuronidase inhibitors. Bioorganic & Medicinal Chemistry, 24(16), 3624–3635.

Abbas, A., Ali, B., Khan, K. M., Iqbal, J., Rahman, S. U., Zaib, S., Perveen, S. (2019). Synthesis and in vitro urease inhibitory activity of benzohydrazide derivatives, in silico and kinetic studies. Bioorganic Chemistry, 82, 163–177.

Ali, B., Khan, K. M., Hussain, S., Hussain, S., Ashraf, M., Riaz, M., Wadood, A., … (2018). Synthetic nicotinic/isonicotinic thiosemicarbazides: In vitro urease inhibitory activities and molecular docking studies. Bioorganic Chemistry, 79, 34–45.

Naz, F., Latif, M., Salar, U., Khan, K. M., Al-Rashida, M., Ali, I., Ali, B., Taha, M., … (2020). 4-Oxycoumarinyl linked acetohydrazide Schiff bases as potent urease inhibitors. Bioorganic Chemistry, 105, 104365.

Salar, U., Khan, K. M., Taha, M., Ismail, N. H., Ali, B., Perveen, S., Ghufran, M., … (2017). Biology-oriented drug synthesis (BIODS): In vitro β-glucuronidase inhibitory and in silico studies on 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethyl aryl carboxylate derivatives. European Journal of Medicinal Chemistry, 125, 1289–1299.

Ali, M., Khan, K. M., Salar, U., Ashraf, M., Taha, M., Wadood, A., Hamid, S., Riaz, M., … (2018). Synthesis, in vitro α-glucosidase inhibitory activity, and in silico study of (E)-thiosemicarbazones and (E)-2-(2-(arylmethylene)hydrazinyl)-4-arylthiazole derivatives. Molecular Diversity, 22(4), 841–861.

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Nitika Mor | Drug Discovery and Development | Best Researcher Award

Dr. Nitika Mor, Baba Mastnath University, Asthal Bohar, Rohtak (HR), India

Dr. Nitika Mor is an accomplished Assistant Professor of Chemistry at Baba Mastnath University, Rohtak, with a Ph.D. in Pharmaceutical Chemistry from Kurukshetra University. Her research focuses on drug delivery systems, traditional medicinal formulations, and molecular docking. She has published 14 research papers, authored a book chapter, holds two patent publications (one granted), and has received multiple awards including the UGC-CSIR JRF/SRF and Best Poster Award. With technical expertise in synthesis, biological assays, and in-silico studies, Dr. Mor is a dynamic contributor to pharmaceutical research and innovation.

Publication Profile

Google Scholar

Education

Dr. Nitika Mor is a dedicated researcher with a Ph.D. in Chemistry from Kurukshetra University (2017–2022), where she focused her thesis on the Design, Characterization, and In-Vitro Studies of Sustained Release Delivery Systems for Curcumin under the guidance of Dr. Neera Raghav. 🎓 She holds an M.Sc. in Organic Chemistry (2013–2015) from Hindu College, Sonipat, affiliated with Maharishi Dayanand University, Rohtak. 🧪 Her academic journey began with a B.Sc. in Physics, Chemistry, and Mathematics (2010–2013) from Hindu Girls College, Sonipat. 📚 Dr. Mor’s educational background reflects a strong foundation in science and innovative pharmaceutical research.

Experience

Dr. Nitika Mor is currently serving as an Assistant Professor in the Department of Chemistry at Baba Mastnath University, Rohtak, since February 1, 2023. 🏛️ With her strong academic foundation and research expertise in pharmaceutical and organic chemistry, she brings innovative teaching methods and deep subject knowledge to the classroom. 🧪 Her role involves mentoring students, delivering engaging lectures, and contributing to the academic growth of the department. 📚 Dr. Mor’s commitment to education and passion for chemistry make her a valuable asset to the university’s faculty. ✨ She continues to inspire budding scientists through her teaching and guidance.

Awards

Dr. Nitika Mor has received several prestigious awards and fellowships in recognition of her academic excellence and research potential. She qualified the UGC-CSIR JRF (Chemical Sciences) in June 2016 with an impressive All India Rank of 65. 🇮🇳 She was awarded the Junior Research Fellowship (JRF) from October 2017 to September 2019, followed by the Senior Research Fellowship (SRF) from October 2019 to March 2022 by UGC-CSIR India to support her Ph.D. journey. 🔬 In 2018, she received the Best Poster Presentation Award at the 9th National Conference on RACES-2018 held at MMM College, Patiala, Punjab.

Research Focus

Dr. Nitika Mor specializes in pharmaceutical and biomedical sciences, with a strong research focus on natural polymer-based oral drug delivery systems. Her work emphasizes the use of biopolymers like cellulose, pectin, carrageenan, and alginate for sustained release formulations, particularly for curcumin. She explores modifications of polysaccharides and curcumin derivatives to improve bioavailability, pharmacokinetics, and therapeutic efficacy. Her contributions also span phytochemistry, investigating medicinal plants like Ashwagandha and Garlic for their pharmacological benefits. Dr. Mor integrates green chemistry, molecular modeling, and clinical insights into her innovative drug delivery strategies.

Publication Top Notes

Recent advances in cellulose, pectin, carrageenan and alginate-based oral drug delivery systems

Some cetyltrimethylammonium bromide modified polysaccharide supports as sustained release systems for curcumin

Design and development of carboxymethylcellulose ester of curcumin as sustained release delivery system in liver

Synthesis of propynyloxy substituted some novel aurones as potent cathepsin B inhibitors

Alginate hydrogels: Sustained release system to analyze the effect of traditional excipients on curcumin availability

Study on enhanced serum protein protecting and anti-cathepsin activities of various curcumin formulations containing traditional excipients and bio-enhancers

In-vitro simulation of modified-alginate ester as sustained release delivery system for curcumin

Curcumin, the panacea: A review on advancement to solve pharmaco-kinetic problems.

A review: Phytochemicals and bioactivities of Ashwagandha (Withania somnifera).

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Prof. Fatma YURT|pharmaceuticals | Best Researcher Award

Prof. Fatma YURT |pharmaceuticals|Best Researcher Award|

Prof. Fatma YURT atEge University,Turkey

PROFILE  

scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Fatma Yurt’s journey into the scientific world began at Ege University, one of Turkey’s leading institutions. She completed her undergraduate studies at the Faculty of Science in the Department of Chemistry between 1982 and 1987. Her passion for science and dedication to learning set the stage for her illustrious career in nuclear sciences. Following her bachelor’s degree, she pursued a doctorate at Ege University in the Institute of Nuclear Sciences, specializing in Nuclear Sciences. From 1991 to 1998, she immersed herself in the study of nuclear applications, gaining a deep understanding of the field’s complexities and potential. This period of intense academic focus and research laid a solid foundation for her future contributions to nuclear medicine, radiopharmacy, and related fields.

Professional Endeavors 💼

Prof. Dr. Fatma Yurt’s professional career is marked by her steady rise through the academic ranks at Ege University. She began her career as a Research Assistant in the Nuclear Applications Department of the Institute of Nuclear Sciences, where she served from 1994 to 1997. This role allowed her to engage in cutting-edge research and contribute to the development of nuclear sciences in Turkey.

In 1999, she was promoted to Assistant Professor, and later in the same year, she achieved the rank of Associate Professor. Her commitment to education and research was evident as she continued to mentor students and lead research projects in nuclear applications. By 2007, she had earned the title of Professor, solidifying her position as a leading expert in her field.

Prof. Dr. Yurt’s expertise is not limited to academia; she has also held significant administrative roles. Since 2016, she has served as the Director of the Institute of Nuclear Sciences at Ege University. In this capacity, she has been instrumental in shaping the direction of nuclear research and education in Turkey, overseeing various projects and initiatives that have expanded the institute’s influence both nationally and internationally.

Contributions and Research Focus 🔬

Prof. Dr. Fatma Yurt’s research spans several critical areas within nuclear sciences, with a particular emphasis on nuclear medicine, radiopharmacy, and pharmacology. Her work in these fields has been pivotal in advancing the understanding and application of nuclear techniques in medicine, particularly in diagnosing and treating various diseases.

Her research contributions include the development of novel radiopharmaceuticals, which are essential for diagnosing and treating conditions such as cancer. Prof. Dr. Yurt’s expertise in nuclear chemistry and physical chemistry has enabled her to explore the intricate processes involved in the synthesis and application of these compounds. She has also contributed significantly to the field of health sciences, particularly in the areas of internal medicine and pharmaceutical technology.

With a Scopus publication count of 123 and a Unisis publication count of 296, Prof. Dr. Yurt’s research output is impressive. Her work has been cited over 1,447 times on Scopus, reflecting the impact and relevance of her research. Her H-Index, a measure of both the productivity and citation impact of her publications, stands at 21 on Scopus, further underscoring her influence in the field.

Accolades and Recognition 🏆

Throughout her career, Prof. Dr. Fatma Yurt has received numerous accolades and recognition for her contributions to nuclear sciences and medicine. Her research has been widely acknowledged by her peers, and she has been invited to present her findings at various national and international conferences. Her role as the Director of the Institute of Nuclear Sciences is a testament to her leadership abilities and her dedication to advancing the field of nuclear applications.

Prof. Dr. Yurt’s work has not only advanced scientific understanding but has also had a tangible impact on healthcare. Her contributions to radiopharmacy have been particularly significant, with her research playing a crucial role in the development of new diagnostic and therapeutic methods. Her dedication to her field is further demonstrated by her ongoing involvement in academic mentorship, helping to train the next generation of scientists in nuclear sciences.

Impact and Influence 🌍

Prof. Dr. Yurt’s influence extends beyond her research and academic roles. As a leader in nuclear sciences, she has been instrumental in promoting the importance of nuclear applications in medicine and other fields. Her work has helped to bridge the gap between basic research and practical applications, ensuring that the benefits of nuclear science are realized in clinical settings.

Her leadership at the Institute of Nuclear Sciences has also been pivotal in shaping the research agenda in Turkey, encouraging interdisciplinary collaboration and fostering a culture of innovation. Under her guidance, the institute has strengthened its position as a center of excellence in nuclear research, attracting students and researchers from around the world.

Legacy and Future Contributions 🌟

Prof. Dr. Fatma Yurt’s legacy is one of dedication, innovation, and leadership. Her contributions to nuclear medicine, radiopharmacy, and related fields have had a lasting impact on both the scientific community and the broader healthcare sector. As she continues her work, her influence will undoubtedly grow, inspiring new research and leading to further advancements in nuclear applications.

🎓Publication 

An in vitro evaluation of Hypericum perforatum loaded-chitosan nanoparticle/agarose film as a Wound dressing

Unveiling combat strategies against Candida spp. biofilm structures: Demonstration of photodynamic inactivation with innovative phthalocyanine derivatives

Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid β1–42 Aggregation

In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer

  • Authors   :Tunçel, A., Maschauer, S., Prante, O., Yurt, F.
  • Journal    :Pharmaceuticals
  • Year         :2024